Efficacy and Safety of a Novel Vascular Closure Device (Glubran 2 Seal) After Diagnostic and Interventional Angiography in Patients with Peripheral Arterial Occlusive Disease

Corso, Antonella Del; Bargellini, Irene; Cicorelli, Antonio; Perrone, Orsola; Leo, Michele; Lunardi, Alessandro; Alberti, Aldo; Tomei, Francesca; Cioni, Roberto; Ferrari, Mauro; Bartolozzi, Carlo

doi:10.1007/s00270-012-0428-7

Cited by 8 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not discover any other studies on this topic, apart from cyanoacrylate-related vascular embolism and arterial intervention-site repair 20,21. These resources specify the superior adhesion characteristic of cyanoacrylate and its low fibrosis rate during the follow-up period.…”

Section: Discussionmentioning

confidence: 93%

Administration of perivascular cyanoacrylate for the prevention of cellular damage in saphenous vein grafts: an experimental model

Kahraman

Yümün

Gücü

et al. 2016

CVJA

View full text Add to dashboard Cite

SummaryObjective:The saphenous vein is the most commonly used graft in coronary artery bypass surgery, since no suitable arterial graft is available. However, the frequency of late graft failure is a cause for research into graft protection. The objective of this study was to investigate the effect of synthetic adhesive cyanoacrylate administration on the saphenous vein graft for preventing vascular damage due to internal pressure on the graft.Methods:In this study we enrolled 20 volunteer subjects who had undergone coronary artery bypass surgery and who had excess saphenous vein grafts. Perivascular cyanoacrylate was administered to one of two saphenous vein grafts explanted from each patient. The other saphenous vein graft from each patient was not treated and was used as the control. A model of the arterial system was created using a saphenous vein cardiopulmonary bypass system. Circulation was maintained at 120 mmHg for 45 minutes. Afterwards, the grafts were subjected to histopathological examination.Results:The cyanoacrylate group of grafts did not develop severe vascular damage compared with many instances of moderate and severe damage due to compression in the control group of grafts (p = 0.003).ConclusionPerivascular administration of cyanoacrylate appeared to be successful in the prevention of early saphenous vein graft injury. No in vivo study has been performed to date to assess endothelial damage in the saphenous vein, in order to demonstrate the long-term effect of cyanoacrylate. Further investigations are needed in this regard.

show abstract

Section: Discussionmentioning

confidence: 93%

Administration of perivascular cyanoacrylate for the prevention of cellular damage in saphenous vein grafts: an experimental model

Kahraman

Yümün

Gücü

et al. 2016

CVJA

View full text Add to dashboard Cite

show abstract

“…The current closure technique involved the standard deployment of a single ProGlide (at a 12 o'clock position) followed by the injection of a mixture of surgical glue (Glubran® 2) and Lipiodol (Lipiodol® Ultra Fluid) in a ratio of 1:2 around the vessel wall and puncture route ( Figure 2A ). Glubran glue, a cyanoacrylate-based tissue glue was proved safe and effective for access closure in a previous study ( 13 ). Notably, the specific Glubran applicator was not used in our study which was applied in previous studies in 5–6 or 7–8F sizes ( 7 , 13 ).…”

Section: Methodsmentioning

confidence: 97%

“…Glubran glue, a cyanoacrylate-based tissue glue was proved safe and effective for access closure in a previous study ( 13 ). Notably, the specific Glubran applicator was not used in our study which was applied in previous studies in 5–6 or 7–8F sizes ( 7 , 13 ). Instead, an improvised applicator was made by simply cutting off the valve from a regular 10F sheath (IntroducerII™, Terumo Medical) and use the remaining tube over the Perclose sutures (not over the guidewire) as the Glubran applicator ( Figure 2B ).…”

Section: Methodsmentioning

confidence: 97%

Feasibility of a modified hybrid glubran-supported single-proglide technique for access closure during endovascular aneurysm repair

Xu,

Chen

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectiveThis study aimed to evaluate the feasibility of a hybrid Glubran-supported single-Proglide technique for large bore femoral access closure during percutaneous access endovascular aneurysm repair (EVAR).MethodsA retrospective cohort study was performed for all percutaneous EVARs at our center from January 2023 to June 2023. All patients received the hybrid Glubran-supported single-Proglide technique involving a mixture of surgical glue and Lipiodol injection after single suture placement for femoral access closure. Technical success was defined as achieving complete hemostasis without a bailout strategy. Vascular complications and bleeding were defined by Valve Academic Research Consortium-3 (VARC-3) criteria. Vascular access changes and 30-day mortality were recorded.ResultsThe technique success rate for the entire study population was 100% (55 femoral access in 37 patients; median age: 72; 78% males). The mean sheath size was 20.4 ± 2.3F. The mean manual compression time was 3.5 ± 1.4 min, the mean hemostasis time was 9.0 ± 2.5 min, and the mean procedural time was 103.9 ± 34.7 min. One patient (1.6%) developed an access site infection and recovered conservatively. No VARC-3 vascular complications and access changes were observed. No 30-day mortality happened.ConclusionsThe hybrid Glubran-supported single-Proglide technique is feasible for large bore access closure during EVAR and may be a viable alternative; however, larger prospective studies are required to confirm its efficacy.

show abstract

“…Next, the fibrin and cells are maintained under standard culture conditions for 24 h and the construct is then ready to be implanted. Surgical glue must be used to seal the edge of the patch to the myocardium to fulfil the required safety and compatibility standards for experimental animals and humans (Del Corso et al , ). In pigs, up to 10 7 cells can be included in the thrombin solution (2.5 ml ∼400 IU/ml solution), then fibrin monomers (from a 100 mg/ml solution) begin to aggregate to form the semi‐solid biomatrix (Liu et al , ).…”

Section: Preparation Of 3d Fibrin–cell Patches: Practical and Scalingmentioning

confidence: 99%

Fibrin, the preferred scaffold for cell transplantation after myocardial infarction? An old molecule with a new life

Roura

Gálvez‐Montón

Bayés‐Genís

2016

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Fibrin is a topical haemostat, sealant and tissue glue, which consists of concentrated fibrinogen and thrombin. It has broad medical and research uses. Recently, several studies have shown that engineered patches comprising mixtures of biological or synthetic materials and progenitor cells showed therapeutic promise for regenerating damaged tissues. In that context, fibrin maintains cell adherence at the site of injury, where cells are required for tissue repair, and offers a nurturing environment that protects implanted cells without interfering with their expected benefit. Here we review the past, present and future uses of fibrin, with a focus on its use as a scaffold material for cardiac repair. Fibrin patches filled with regenerative cells can be placed over the scarring myocardium; this methodology avoids many of the drawbacks of conventional cell-infusion systems. Advantages of using fibrin also include extraction from the patient's blood, an easy readjustment and implantation procedure, increase in viability and early proliferation of delivered cells, and benefits even with the patch alone. In line with this, we discuss the numerous preclinical studies that have used fibrin-cell patches, the practical issues inherent in their generation, and the necessary process of scaling-up from animal models to patients. In the light of the data presented, fibrin stands out as a valuable biomaterial for delivering cells to damaged tissue and for promoting beneficial effects. However, before the fibrin scaffold can be translated from bench to bedside, many issues must be explored further, including suboptimal survival and limited migration of the implanted cells to underlying ischaemic myocardium. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Efficacy and Safety of a Novel Vascular Closure Device (Glubran 2 Seal) After Diagnostic and Interventional Angiography in Patients with Peripheral Arterial Occlusive Disease

Abstract: In patients with PAOD, the Glubran 2 Seal represents a simple, painless, and efficient vascular closure device, able to achieve hemostasis both in antegrade and retrograde accesses.

Cited by 8 publications

References 10 publications

Administration of perivascular cyanoacrylate for the prevention of cellular damage in saphenous vein grafts: an experimental model

Administration of perivascular cyanoacrylate for the prevention of cellular damage in saphenous vein grafts: an experimental model

Feasibility of a modified hybrid glubran-supported single-proglide technique for access closure during endovascular aneurysm repair

Fibrin, the preferred scaffold for cell transplantation after myocardial infarction? An old molecule with a new life

Contact Info

Product

Resources

About